Palomar Medical Technologies, Inc. is pleased to announce that the Lux1540™ Fractional non-ablative laser handpiece has received the first clearance by the United States Food and Drug Administration (FDA) for the treatment of striae (stretch marks) using a fractional laser. This new clearance will allow aesthetic practitioners to treat the millions of women worldwide who have unwanted stretch marks. Ongoing clinical studies have shown that subjects treated with the Lux1540 achieved an average improvement of between 51% and 75% in the appearance of their striae, based upon a blinded review of photographs comparing the pre-treatment appearance of striae versus the results three months post-treatment.
Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary treatment system for metastatic cancers to the liver, announced that sufficient events have been reached to allow data analysis to begin on its Phase III trial. The trial uses the drug melphalan to treat patients with metastatic melanoma in the liver. "We remain very optimistic that the Phase III trial will achieve a successful endpoint, " said Eamonn P. Hobbs, President and CEO of Delcath. "Assuming a successful trial endpoint, we remain committed to filing our NDA with the FDA in April, " Mr. Hobbs added. The 92 patient, randomized, multi-center, Phase III study commenced patient enrollment in February 2006.
Using lasers and nanoparticles, scientists at Rice University have discovered a new technique for singling out individual diseased cells and destroying them with tiny explosions. The scientists used lasers to make "nanobubbles" by zapping gold nanoparticles inside cells. In tests on cancer cells, they found they could tune the lasers to create either small, bright bubbles that were visible but harmless or large bubbles that burst the cells. "Single-cell targeting is one of the most touted advantages of nanomedicine, and our approach delivers on that promise with a localized effect inside an individual cell, " said Rice physicist Dmitri Lapotko, the lead researcher on the project.
St. Jude Medical Announces European Approval Of Smaller, Higher Power ICD And CRT-D Devices With New Heart Failure Monitors
St. Jude Medical, Inc. (NYSE:STJ) announced European CE Mark approval and first implants of its Fortify(TM) and Fortify ST implantable cardioverter defibrillators (ICD) and Unify(TM) cardiac resynchronization therapy defibrillator (CRT-D). The devices will be fully launched in Europe later this spring, and U.S. versions of the Fortify ICD and Unify CRT-D are expected to be launched later this year. The reduced size of these new devices compared to those of previous generations creates the smallest available device footprint in the industry. The Fortify ICD and Unify CRT-D feature advanced battery technology and circuitry that allow for a smaller device, with more energy capacity and rapid charge times, all while increasing device longevity.
Testing has begun on a device that can sniff out the presence of disease by smell, thanks to a 1.3 million pound award from the Wellcome Trust. OdoReader, developed by Chris Probert from the University of Bristol and Norman Ratcliffe from the University of the West of England, uses pioneering technology to rapidly diagnose Clostridium difficile, by 'reading' the odour of stool samples. Clostridium difficile may cause severe diarrhoea, especially amongst hospitalised patients. With the help of University Hospitals Bristol NHS Foundation Trust, the technology enables gasses emitted from faeces to be analysed in under an hour, leading to a rapid and inexpensive diagnosis.
A mystical glow emanates from the display case. A white light appears out of nowhere. And a light source is invisible - at least at first glance. Only upon close examination does the source of the apparently supernatural illumination become visible: a light diode, smaller than a pinhead, passes through thousands of infinitesimal lens structures measuring only a few hundred nanometers, et voila: beaming white light. "For a long time, producing white light with no peripheral color effects was an almost unsolvable technical problem, " explains Dr. Michael Popall of the Fraunhofer Institute for Silicate Research ISC in Wurzburg. "White light is produced by mixing the complementary colors red, green and blue.